Free Trial

Motus GI Q4 2023 Earnings Report

Motus GI EPS Results

Actual EPS
-$4.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Motus GI Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Motus GI Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Remove Ads

Motus GI Earnings Headlines

New Pick (93% history of rising by May 8)
We just posted a new recommendation. Keep in mind: You could have boosted the Netflix trade we issued to the public back in January to a 268% gain in 14 days. Our newest pick has a 93% history of rising by May 8 at a rate fast enough to double your money, if you were to make trades of this caliber again and again, which we'll show you how to do.
See More Motus GI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Motus GI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Motus GI and other key companies, straight to your email.

About Motus GI

Motus GI (NASDAQ:MOTS) operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

View Motus GI Profile

More Earnings Resources from MarketBeat